Swedish Orphan Biovitrum AB (publ) Sobi® (STO: SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announce the completion of the acquisition of Arthrosi by Sobi. Arthrosi Therapeutics is a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi’s gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026.
Read the full article: Sobi Completes Acquisition of Arthrosi Therapeutics, Strengthening Pipeline for the Potential Treatment of Gout //
Source: https://www.prnewswire.com/news-releases/sobi-completes-acquisition-of-arthrosi-therapeutics-strengthening-pipeline-for-the-potential-treatment-of-gout-302682651.html